Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar-Apr;36(2):576-581.
doi: 10.21873/invivo.12740.

The Effects of Analgesics on the Migration of Pancreatic Cancer Cells

Affiliations

The Effects of Analgesics on the Migration of Pancreatic Cancer Cells

Manuela Malsy et al. In Vivo. 2022 Mar-Apr.

Abstract

Background/aim: Adenocarcinoma of the pancreas is one of the most aggressive malignant diseases in humans. Characteristics of this tumour type are poor response to radiotherapy and chemotherapeutic agents as well as metastasis in the absence of an organ capsule. The best therapeutic option is surgical removal of the tumour followed by chemotherapy or radiotherapy. Yet, even after surgical R0-resection, the 5-year survival probability is only about 20% because of the high recurrence rate of this tumour and complications due to metastases. Furthermore, recent studies have shown that the perioperative period is a particularly vulnerable phase, during which tumour progression and metastasis may be facilitated. The effects of analgesics administered during the perioperative period are still unknown. The present work investigated the effects of analgesics on pancreatic cancer cell migration in vitro.

Materials and methods: The migratory potential of pancreatic cancer cells was analysed using a Cell Migration Assay Kit with a Boyden chamber, in which cells migrate through a semi-permeable membrane under different stimuli. Cell concentration was measured by reading fluorescence (Ex/Em=530/590 nm) in a plate reader.

Results: Migration in PANC-1 pancreatic cancer cells was significantly decreased after 24 h stimulation with 100 μM of ropivacaine, 100 nM of sufentanil, 1,000 μM of ropivacaine and 1,000 nM of sufentanil. In the PaTu 8988t cell line, incubation with 10 μM of ropivacaine caused a slight but statistically significant increase in migration, whereas lidocaine, metamizole and paracetamol did not significantly affect migration.

Conclusion: The risk of tumour progression and metastasis seems to be increased during major oncological surgical interventions. The recent advances in the molecular and biological understanding of pathogenesis of pancreatic cancer have not yet significantly improved patient outcome. Therefore, further studies are needed to identify the underlying mechanisms of this aggressive tumour and establish new therapeutic options for the future.

Keywords: Migration; analgesics; cancer; lidocaine; metamizole; pancreatic cancer; paracetamol; ropivacaine; sufentanil.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. The effects of metamizole and paracetamol on cell migration in PaTu 8988t (a) and PANC-1 (b) pancreatic cancer cells in vitro. Cell migration was quantified by using a Boyden chamber in which cells migrate through a semi-permeable membrane under different stimuli. *Statistical significance at p<0.05 compared to untreated controls.
Figure 2
Figure 2. The effects of lidocaine, ropivacaine and sufentanil and the combination of ropivacaine and sufentanil on migration in PaTu 8988t (a) and PANC-1 (b) pancreatic cancer cells in vitro. The cell migration rate was detected by using a Boyden chamber in which cells migrate through a semi-permeable membrane under different stimuli. *Statistical significance at p<0.05 compared to untreated controls.

Similar articles

Cited by

References

    1. Kaatsch P, Spix C, Katalinic A, Hentschel S, Luttmann S, Stegmaier C, Waldeyer- Sauerland M, Waldmann A, Caspritz S, Christ M, Ernst A, Folkerts J, Hansmann J, Klein S. Krebs in Deutschland 2013/2014. Berlin, Robert Koch-Institute, 2017. Available at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutsc.... [Last accessed on February 9, 2022]
    1. Schmid RM. [Pancreatic cancer] Praxis (Bern 1994) 2006;95(44):1709–1712. doi: 10.1024/1661-8157.95.44.1709. - DOI - PubMed
    1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218–1249. doi: 10.1101/gad.1415606. - DOI - PubMed
    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–1057. doi: 10.1016/S0140-6736(04)15841-8. - DOI - PubMed
    1. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326(7):455–465. doi: 10.1056/NEJM199202133260706. - DOI - PubMed